The last xigris ®* survivor

Surgical Infections

Volumn 12, Issue 6, 2011, Pages 423-425

  Barie, Philip S ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

DROTRECOGIN; HEPARIN; HYPERTENSIVE AGENT; NORADRENALIN; PLACEBO;

ABDOMINAL INFECTION; AGED; ANTIBIOTIC THERAPY; BRONCHOSCOPY; CASE REPORT; CHEMOPROPHYLAXIS; CLINICAL TRIAL (TOPIC); COMPUTER ASSISTED TOMOGRAPHY; DRUG MARKETING; DRUG WITHDRAWAL; EDITORIAL; ENDOTRACHEAL INTUBATION; ESCHERICHIA COLI; HUMAN; INTENSIVE CARE UNIT; LUNG LAVAGE; MALE; MORTALITY; NASOGASTRIC TUBE; NAUSEA; PARALYTIC ILEUS; PNEUMONIA; POSITIVE END EXPIRATORY PRESSURE; POSTOPERATIVE PERIOD; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROSTATECTOMY; PULMONARY ASPIRATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); SEPTIC SHOCK; SPUTUM EXAMINATION; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME; TACHYCARDIA; TACHYPNEA; VENOUS THROMBOEMBOLISM; VOMITING;

AGED; ANTI-INFECTIVE AGENTS; DRUG APPROVAL; DRUG RECALLS; HUMANS; MALE; PNEUMONIA, ASPIRATION; PNEUMONIA, BACTERIAL; PROTEIN C; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECOMBINANT PROTEINS; SHOCK, SEPTIC; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME;

EID: 84555179054     PISSN: 10962964     EISSN: 15578674     Source Type: Journal    
DOI: 10.1089/sur.2011.9909     Document Type: Editorial

References (17)

1. Dellinger RP, Levy MM, Carlet JM, et al; International Sur-viving Sepsis Campaign Guidelines Committee; American Association of Critical-Care Nurses; American College of Chest Physicians; American College of Emergency Physi-cians; Canadian Critical Care Society; European Society of Clinical Microbiology and Infectious Diseases; European Society of Intensive Care Medicine; European Respiratory Society; International Sepsis Forum; Japanese Association for Acute Medicine; Japanese Society of Intensive Care Medicine; Society of Critical Care Medicine; Society of Hospital Medicine; Surgical Infection Society; World Fed-eration of Societies of Intensive and Critical Care Medicine. Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock: 2008. Crit Care Med 2008;36:296-327. Erratum in: Crit Care Med 2008;36:1394-1396.
2. Barie PS, Hydo LJ, Shou J, et al. Influence of antibiotic therapy on mortality of critical surgical illness caused or complicated by infection. Surg Infect (Larchmt) 2005;6:41-54. (Pubitemid 40711364)
3. Barie PS, Hydo LJ, Fischer E. Comparison of APACHE II and III scoring systems for mortality prediction in critical surgical illness. Arch Surg 1995;130:77-82.
4. Lilly announces withdrawal of Xigris® following recent clinical trial results. https://investor.lilly.com/releasedetail2 .cfm?ReleaseID = 617602. Accessed November 17, 2011.
5. Barie PS. ''All in'' for a huge pot: the PROWESS-SHOCK trial for refractory septic shock. Surg Infect (larchmt). 2007 Oct;8(5):491-494.
6. Finfer S, Ranieri VM, Thompson BT, et al. Design, conduct, analysis and reporting of a multi-national placebo-controlled trial of activated protein C for persistent septic shock. In-tensive Care Med 2008;34:1935-1947. Erratum in: Intensive Care Med 2011;37:372.
7. Bernard GR, Vincent JL, Laterre PF, et al. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 2001;344:699-709. (Pubitemid 32204987)
8. Talmor M, Hydo L, Barie PS. Relationship of systemic in-flammatory response syndrome to organ dysfunction, length of stay, and mortality in critical surgical illness: Effect of intensive care unit resuscitation. Arch Surg 1999;134: 81-87. (Pubitemid 29047222)
9. Barie PS, Hydo LJ, Shou J, Eachempati S.R. Efficacy of ther-apy with recombinant human activated protein C of criti-cally ill surgical patients with infection complicated by septic shock and multiple organ dysfunction syndrome. Surg Infect 2011;12:443-449.
10. Russell JA, Walley KR, Singer J, et al.; VASST Investigators. Vasopressin versus norepinephrine infusion in patients with septic shock. N Engl J Med 2008;28;358:877-887. (Pubitemid 351397087)
11. Sprung CL, Annane D, Keh D, et al. CORTICUS Study Group. Hydrocortisone therapy for patients with septic shock. N Engl J Med 2008;358:111-124.
12. Thompson BT, Ranieri VM, Finfer S, et al. Statistical analysis plan of PROWESS SHOCK study. PROWESS SHOCK Steering Committee, Intensive Care Med. 2010;36: 1972-1973.
13. Ranieri VM, Thompson BT, Finfer S, et al. Unblinding plan of PROWESS-SHOCK trial. PROWESS-SHOCK Aca-demic Steering Committee. Intensive Care Med 2011;37: 1384-1385.
14. Barie PS. An opinion too far-the campaign against the Surviving Sepsis Campaign. Surg Infect (Larchmt) 2006;7: 485-488. (Pubitemid 46348298)
15. Barie PS. Current role of activated protein C therapy for severe sepsis and septic shock. Curr Infect Dis Rep 2008; 10:368-376.
16. Abraham E, Laterre PF, Garg R, et al. Administration of Drotrecogin Alfa (Activated) in Early Stage Severe Sepsis (ADDRESS) Study Group. Drotrecogin alfa (activated) for adults with severe sepsis and a low risk of death. N Engl J Med 2005;353:1332-1341.
17. Barie PS, Eachempati S.R. Consequences of failed source control. In Schein M, Marshall JC, eds. Source Control. Berlin, Springer-Verlag 2003:71-81.